2021 Guide to Patient Support Services

2021 Oncology Guide to Patient Support Services

The Guide to Patient Support Services Index can be sorted by Drug or Company to help you quickly access information about programs offered by pharmaceutical companies and novel cancer drugs approved in 2020. Read More ›

As the number of innovative and ever-improving cancer therapies introduced to the market continues to grow each year, so do the economic difficulties these life-saving medications pose to patients and their families. Read More ›

Agios Pharmaceuticals offers the myAgios Patient Support Services, a program that provides a suite of support services for patients who have been prescribed Tibsovo (ivosidenib). Read More ›

Amgen Assist 360 provides several support services for insured, uninsured, and underinsured patients who encounter financial hardships and cannot afford the Amgen medications they are prescribed, including Amgen FIRST STEP and the Amgen Safety Net Foundation. Read More ›

Astellas Pharma’s Support Solutions offers several support services to eligible patients who are prescribed Astellas Pharma’s oncology medications, including Xospata (gilteritinib), Xtandi (enzalutamide), and Padcev (enfortumab vedotin-ejfv). Read More ›

AstraZeneca, through its Access 360 and AZ&Me programs, offers a range of patient support programs and drug-specific patient savings programs to help patients access affordable AstraZeneca medications. Read More ›

Bayer HealthCare offers comprehensive support services for eligible patients who are prescribed Bayer oncology drugs through its Oncology $0 Co-Pay Program, the REACH (Resources for Expert Assistance and Care Helpline) program, the Xofigo Access Services program, Vitrakvi TRAK Assist, DUDE (Darolutamide User Drug Experience) Access Services, and the Aliqopa Resource Connections program. Read More ›

BeiGene, through its myBeiGene Patient Support Program, provides customized and personalized support services for providers and for patients, including reimbursement and payment support services, such as insurance verification and prior authorization, in addition to direct assistance for patients who are prescribed Brukinsa (zanubrutinib). Read More ›

Blueprint Medicines’ YourBlueprint support program offers a wide array of personalized support services, including access and reimbursement assistance for providers and financial assistance for patients who are prescribed Blueprint’s oncology drugs, Ayvakit (avapritinib) tablets or Gavreto (pralsetinib) capsules. Read More ›

Boehringer Ingelheim’s Gilotrif Patient Services includes a range of programs and services offered through the company’s Solutions Plus program. This program provides support, education, and reimbursement services to patients who are prescribed Gilotrif (afatinib), as well as to their providers. Read More ›

Through its Access Support program, Bristol Myers Squibb (BMS) offers a variety of oncology support options for patients receiving outpatient treatment in the United States and Puerto Rico. Read More ›

Celgene Corporation offers patient support services for patients receiving Celgene medications through the Celgene Patient Support program. This program offers eligible patients a range of support services to access Celgene’s oncology drugs, regardless of their insurance status. Read More ›

Clovis Oncology’s Rubraca Connections is a comprehensive patient support services program, including the Rubraca Connections $0 Co-Pay Program, the Rubraca Connections QuickStart Program, and the Rubraca Connections Patient Assistance Program. Read More ›

Coherus BioSciences’ Coherus COMPLETE offers comprehensive reimbursement and patient support services for patients receiving treatment with Udenyca (pegfilgrastim-cbqv) who are unable to afford this medication, along with provider service programs to help access Udenyca and secure patient reimbursements. Read More ›

Daiichi-Sankyo’s Access Central offers comprehensive reimbursement and patient support services for patients who are prescribed Injectafer (ferric carboxymaltose injection) or Turalio (pexidartinib) but are unable to afford their medication. Read More ›

Page 1 of 4

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: